Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1079 in Advanced Solid Tumors
NCT07387068Phase 1Recruiting
- Sponsor
- Genmab
- Start
- Apr 2026
- Primary completion
- Jan 2031
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of GEN1079 in solid tumor (3 arms), sponsored by Genmab. Primary endpoints: Dose-limiting Toxicities at 21 days, Adverse Events at 67 weeks and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
GEN1079
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07387068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387068.